Bullish Moving Averages
16
Bearish Moving Averages
0
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Open Price
2250.20Prev. Close
1835.9000Volume
4063792.00Value
10570329371.20Fundamentals
Market Cap
27211.70
Price to Earnings
86.90
Price to Book Value
17.80
Dividend Yield
0.30
PE to Growth
3.10
Op Revenue TTM
1037.91
Net Profit TTM
313.20
Cash From Operating Activity
265.47
Return on Equity %
20.18
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
19 Sep, 2024
53.3
Week
45.8
Month
34.6
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
2227.67
PIVOT
First Resistance
2322.83
Second Resistance
2395.12
Third Resistance
2490.28
First Support
2155.38
Second Support
2060.22
Third Support
1987.93
Relative Strength Index
85.18
Money Flow Index
89.01
MACD
139.31
MACD Signal
99.34
Average True Range
104.09
Average Directional Index
51.5
Rate of Change (21)
39.82
Rate of Change (125)
53.09
Day Commodity Channel Index
154.6
Day Williams %R
-12.8
BETA
1 Month
0.21
3 Month
0.62
1 Year
0.36
3 Year
PRICE CHANGE ANALYSIS
↑ 29.75%
1 Week
Low
High
1988.45
2664
↑ 58.41%
1 Month
Low
High
1570
2664
↑ 65.05%
3 Months
Low
High
1460.5
2664
↑ 78.02%
6 Months
Low
High
1327.05
2664
↑ 159.45%
1 Year
Low
High
958.7
2664
12 Sep 2024
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 on 19th September, 2024
12 Sep 2024
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 on 18th September, 2024.
05 Sep 2024
Concord Biotech shares hit all time high; Antique Broking reiterates 'Buy'
Antique Broking is bullish on Concord's business model, new launches and niche products
30 Aug 2024
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.
20 Aug 2024
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
The transcripts of the earning calls for the first quarter ended June 30, 2024 is enclosed herewith. kindly take the same into your records.
12 Aug 2024
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to the provision of Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, and further to our intimation dated August 07, 2024 to the Stock exchanges regarding Earning call in respect of the unaudited (Standalone and Consolidated) Financial Results of the company for the First Quarter ended on June 30, 2024, we wish to inform that the said Earning Call was held today at 03:30 PM (IST). Kindly take the above on records.
10 Aug 2024
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of SEBI (LODR) Regulation 2015, Investor Presentation on financial results for the first quarter ended June 30, 2024, is enclosed Kindly take the above on records
10 Aug 2024
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI(LODR) Regulation, 2015, Please find enclosed herewith Extract of the unaudited standalone and consolidated Financial Results for the first quarter ended June 30, 2024,as published in the below Newspaper on August 10, 2024 Kindly take the above on records
09 Aug 2024
Concord Biotech Ltd - 543960 - Financial Results For 30/06/2024
Unaudited Standalone and Consolidated Financial Statement for the first quarter ended june 30, 2024
09 Aug 2024
Concord Biotech Ltd - 543960 - Board Meeting Outcome for Outcomes Of Board Meeting For The Unaudited Financials Results For The First Quarter Ended On June 30, 2024
With reference to the intimation of Board meeting submitted on July 31, 2024, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, August 09, 2024, has inter-alia, approved Unaudited Standalone and Consolidated Financial Results for the First quarter ended on June 30, 2024. The said results were also reviewed by the Audit Committee of the Company in its meeting held on August 09, 2024.
